Anti-virus therapy of entecavir in the treatment of chronic hepatitis B at the initial stage

Objective To evaluate the 48 weeks therapeutic effect and safety of anti-virus therapy of entecavir in patients with chronic hepatitis B(CHB).Methods 187 CHB cases were divided into the treatment group(118)and the control group(69)randomly.Patients were given entecarvir(0.5mg po qd)in the treatment group,while the others were given lamivudine(100mg po qd)in the control group.Results In the treatment group,the levels of serum HBV DNA at the 4th and 8th week were significantly decreased than that before treatment;the ratio of negative transformation of HBV DNA was 57.6% at the 12th week,which was superior to that in the control group,and there was higher ratio of early response of anti-virus therapy.At the 24th and 48th week,the ratios of negative transformation of HBV DNA were 81.3% and 92.3%,there were significent difference between these two groups.At the 48th week the ratio of negative transformation of HBeAg was separately 28.8% and the ratio of recovery of liver function was 98.3%,and there was no drug-resistant case,which demonstrated favourable reaction of sustained response.There was no serious adverse event related to entecavir.Conclusion Entecavir can inhibit the replication of hepatitis B virus,with good safety and tolerance.